

## Scientific paperwork

### Overview about publications referencing the RoboGene HDV RNA Quantification Assay



#### **ROBOSCREEN – Your reliable Partner for HDV RNA quantification**

With over 20 years of experience in developing diagnostic products, we are proud to have introduced the first CE-IVD labeled HDV RNA quantification assay to the market in 2015.

Our RoboGene assay was used to establish the 1st WHO HDV RNA International Standard in 2013 and was also utilized in various clinical trials to validate multiple therapeutic approaches.

Herein, we list scientific papers for your reference by the year of publication.

## 2026

Asselah T, Chattergoon MA, Jucov A, Streinu-Cercel A, Lampertico P, Wedemeyer H, Kennedy PT, Gane EJ, Bullard BL, Chow S, Santos D, Camus G, Lu Y, Pilowa C, Hwang C, Correll T, Agarwal K; SOLSTICE Trial Investigators. [A Phase 2 Trial of Tobeivart plus Elebsiran in Hepatitis D](#). N Engl J Med. 2026 Jan 22;394(4):343-353. doi: 10.1056/NEJMoa2508827. Epub 2025 Nov 9. PMID: 41211943.

---

Nyarko, E.N.Y., Tachi, K., Kumi, J. et al. [Prevalence and biomarker profiles of HBV/HDV coinfection and occult HBV infection among patients attending Bimbilla Hospital, Northern Ghana](#). BMC Infect Dis (2026). <https://doi.org/10.1186/s12879-026-13881-8>.

---

Wang X, Chi X, Zhang Y, Kong F, Zhou X, Gu Y, Qi Y, Zou L, Zhou Z, Wen J, Chen P, Li G, Zhang Y, Ye B, Chen B, Sui J, Li W, Zhou H, Niu J. [Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China](#). Hepatol Commun. 2026 Jul 15;10(8):e00974. doi: 10.1097/HC9.0000000000000974. PMID: 42486799.

---

Eichholz JC, Bremer B, Wedemeyer H, Maasoumy B, Sandmann L. [Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5](#). J Clin Virol. 2026 Aug;185:105971. doi: 10.1016/j.jcv.2026.105971. Epub 2026 Jun 30. PMID: 42385559.

---

Wedemeyer H, Aleman S, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Lichtman A, Manuilov D, Mercier RC, Arterburn S, Christian-Cox F, Tseng S, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Brunetto MR, Lampertico P. [144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial](#). J Hepatol. 2026 Apr 9:S0168-8278(26)00201-1. doi: 10.1016/j.jhep.2026.03.046. Epub ahead of print. PMID: 41966308.

---

Delagarde V, Gerber A, Dziri S, Chaghouri A, Akhavan S, Gordien E, Le Gal F, Roulot D, Brichler S. [Impact of sensitivity difference between two widely used HDV RNA quantification assays on the management of HDV-infected patients treated with bulevirtide](#). J Virol Methods. 2026 Jul;344:115394. doi: 10.1016/j.jviromet.2026.115394. Epub 2026 Apr 2. PMID: 41935578.

---

Palom A, Degasperi E, Coco B, Loglio A, Ciano A, Niro GA, Riveiro-Barciela M, Carvalho-Gomes A, García-Samaniego J, Lens S, Rando-Segura A, Sambarino D, Cotugno R, Kondili LA, Brunetto M, Viganò M, Lampertico P, Buti M. [Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study](#). Aliment Pharmacol Ther. 2026 Aug;64(3):326-333. doi: 10.1111/apt.70695. Epub 2026 Apr 20. PMID: 42010908; PMCID: PMC13356362.

---



Ghodratian Z, Grikscheit K, Busetto L, Marx B, Kohmer N, Auste A, Scheu R, Harries M, Melhorn V, Illig T, Strengert M, Berger A, Lange B, Ciesek S. [Population-based prevalence and screening gaps of hepatitis C, B and D, Germany, 2020 to 2021](#). Euro Surveill. 2026 Jun;31(25):2500864. doi: 10.2807/1560-7917.ES.2026.31.25.2500864. PMID: 42359548; PMCID: PMC13309759.

---

Ifeorah I, Bremer B, Musa Y, Kahlhöfer J, Oguntoye O, Tishiya C, Aglavidawa G, Ameh O, Abdulkadir Y, Ariyo O, Anim M, **Reinhardt A**, Heim A, George U, Abdulkareem L, Garzali IU, Wedemeyer H, Sandmann L. [Hepatitis delta virus co-infection in patients with hepatocellular carcinoma and people living with HIV in Nigeria](#). BMC Infect Dis. 2026 Feb 26;26(1):699. doi: 10.1186/s12879-026-12913-7. PMID: 41749169; PMCID: PMC13040908.

---

Schwarz M, Hintersteininger M, Schwarz C, Panzer M, Pfisterer N, Loschko N, Hartl L, Dorn L, Laferl H, Trauner M, Stättermayer AF, Mandorfer M, Graziadei I, Maieron A, Moschen A, Aigner E, Stadlbauer V, Madl C, Aberle SW, Zoller H, Gschwantler M, Reiberger T, Jachs M. [Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study](#). JHEP Rep. 2026 Jun;8(6):101835. doi: 10.1016/j.jhepr.2026.101835. Epub 2026 Mar 26. PMID: 41903606; PMCID: PMC13199667.

---

Mhlanga A, Shekhtman L, Goyal A, Degasperis E, Anolli MP, Renteria SCU, Sambarino D, Borghi M, Perbellini R, Facchetti F, Callegaro A, Cotler SJ, Lampertico P, Dahari H. [Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions](#). ArXiv [Preprint]. 2026 Jun 4;arXiv:2505.12286v2. PMID: 42282052; PMCID: PMC13252502.

---

D'Anna S, Piermatteo L, Magnapera A, Grossi I, Tramontozzi C, Olivero A, Duca L, Torre G, Teti E, Di Lorenzo A, Malagnino V, Iannetta M, Girelli S, Paba P, Bertoli A, Ceccherini-Silberstein F, Baiocchi L, Francioso S, Lenci I, Milella M, Saracino A, Ciancio A, Brancaccio G, Sarmati L, Lampertico P, Rizzetto M, Caviglia GP, Salpini R, Svicher V. [Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity](#). Viruses. 2026 Apr 30;18(5):515. doi: 10.3390/v18050515. PMID: 42198718; PMCID: PMC13211560.

---

Zulkhuu D, Kamal H, Enkhtaivan S, Narantsogt O, Jargalsaikhan G, Batkhuu M, Ochirsum B, Ahl M, Lindahl K, Ingre M, Stiglund N, Petropoulos A, Sandh G, Björkström NK, Saario S, Cederberg S, Olsson A, Baye AW, Derdabi I, Georgos D, Bungert AS, Dashdorj NB, Onom NDD, Aleman S. [Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex- and age-matched native Mongol cohort](#). BMC Infect Dis. 2026 Jan 16;26(1):178. doi: 10.1186/s12879-025-12506-w. PMID: 41545934; PMCID: PMC12849161.

---

Wedemeyer H, Gane E, Agarwal K, Tabak ÖF, Forns X, Akarca US, Morozov V, Aleman S, Buti M, Yilmaz G, Lampertico P, Jezorwski J, Kakuda TN, Bakala A, Pehlivanov N, Verbinnen T, Lenz O, Biermer M. [siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares](#). J Hepatol. 2026 Sep;85(3):504-514. doi: 10.1016/j.jhep.2026.05.007. Epub 2026 May 15. PMID: 42142631.

---

## 2025

Stelzl E, Berger A, Ciesek S, Olivero A, Lampertico P, Callegaro A, Renteria SU, Heim A, Aberle SW, Springer DN, Wedemeyer H, Bremer B, Sandmann L, **Reinhardt A, Gey B, Früchtel C, Kessler HH.** [Accurate quantification using the new RoboGene HDV RNA Quantification Kit 3.0: A European multicenter study.](#) J Clin Virol. 2025 Aug;179:105828. doi: 10.1016/j.jcv.2025.105828. Epub 2025 Jun 18. PMID: 40543190.

---

Degasperi E, Anolli MP, Jachs M, Reiberger T, De Ledinghen V, Metivier S, D'Offizi G, di Maria F, Schramm C, Schmidt H, Zöllner C, Tacke F, Dietz-Fricke C, Wedemeyer H, Papatheodoridi M, Papatheodoridis G, Carey I, Agarwal K, Van Bömmel F, Brunetto MR, Cardoso M, Verucchi G, Ciano A, Zoulim F, Aleman S, Semmo N, Mangia A, Hilleret MN, Merle U, Santantonio TA, Coppola N, Pellicelli A, Roche B, Causse X, D'Alteroche L, Dumortier J, Ganne N, Heluwaert F, Ollivier I, Roulot D, Viganò M, Loglio A, Federico A, Pileri F, Maracci M, Tonnini M, Arpurt JP, Barange K, Billaud E, Pol S, Gervais A, Minello A, Rosa I, Puoti M, Lampertico P. [Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.](#) J Hepatol. 2025 Jun;82(6):1012-1022. doi: 10.1016/j.jhep.2024.12.044. Epub 2025 Jan 8. PMID: 39793613.

---

Lampertico P, Bogomolov PO, Chulanov V, Stepanova T, Morozov V, Allweiss L, Dandri M, Burhenne J, Blank A, Ciesek S, Elsner C, Dittmer U, An Q, Manuilov D, Da BL, Flaherty JF, Urban S, Wedemeyer H. [Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFN \$\alpha\$ -2a as Treatment for Chronic Hepatitis Delta.](#) Liver Int. 2025 Feb;45(2):e70008. doi: 10.1111/liv.70008. PMID: 39853842; PMCID: PMC11760647.

---

Sandmann L, Jachs M, Tergast TL, Hartl L, Bremer B, Kabelitz MA, Schwarz M, Egge JFM, Balcar L, Hofer BS, Falk CS, Stättermayer AF, Cornberg M, Trauner M, Deterding K, Mandorfer M, Wedemeyer H, Reiberger T, Maasoumy B. [Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D.](#) JHEP Rep. 2025 Oct 17;8(1):101643. doi: 10.1016/j.jhepr.2025.101643. PMID: 41674894; PMCID: PMC12890450.

---

Sandmann L, Ohlendorf V, Ehrenbauer A, Bremer B, Kraft ARM, Cornberg M, Deterding K, Wedemeyer H, Maasoumy B. [Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection.](#) Liver Int. 2025 Feb;45(2):e70003. doi: 10.1111/liv.70003. PMID: 39846714; PMCID: PMC11756344.

---

Coco B, Quaranta MG, Tosti ME, Ferrigno L, Brancaccio G, Ciano A, Coppola C, Messina V, Gentile I, Claar E, Morisco F, Santantonio T, Viganò M, Cacciola I, Pompili M, Russo FP, Izzi A, Niro GA, Coppola N, Soria A, Federico A, Morsica G, Puoti M, Villa E, Lampertico P, Gaeta GB, Kondili LA, Brunetto MR; PITER Collaborating Investigators. [Sex-based differences in hepatitis delta virus infection: Insights from the Italian PITER hepatitis delta virus cohort.](#) World J Gastroenterol. 2025 Dec 21;31(47):111637. doi: 10.3748/wjg.v31.i47.111637. PMID: 41479753; PMCID: PMC12754152.

---



Salpini R, Piermatteo L, Caviglia GP, Bertoli A, Brunetto MR, Bruzzzone B, Callegaro A, Caudai C, Cavallone D, Chessa L, Coghe F, Coppola N, Cuomo N, D'Anna S, Di Stefano M, Facchetti F, Farina C, Ferraro D, Franchin E, Francisci D, Galli S, Garbuglia AR, Gennari W, Ghisetti V, Lampertico P, Lo Caputo S, Marascio N, Menzo S, Micheli V, Niro GA, Olivero A, Paba P, Palermo CI, Palmieri O, Paolucci S, Pisaturo M, Pollicino T, Raffa G, Santantonio T, Torre G, Turriziani O, Uzzau S, Uceda Renteria SC, Vatteroni M, Zazzi M, Craxì A, Ceccherini-Silberstein F, Svicher V; HCV Virology Italian Resistance Network (VIRONET-C); Arosio M, Bastianelli S, Gentile A, Giardina FAM, Gidari A, Govoni R, Ibba G, Loglio A, Lombardi A, Mascarella C, Maggi F, Matera G, Mazzei C, Milia MG, Quirino A, Raddi A, Scioscia R, Tagliazucchi S, Totaro M, Valaperta R. [Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.](#) J Clin Virol. 2025 Oct;180:105850. doi: 10.1016/j.jcv.2025.105850. Epub 2025 Aug 6. PMID: 40784197.

---

Furquim d'Almeida A, Ho E, Govaerts L, Michielsen P, Sersté T, Bourgeois S, Delwaide J, Moreno C, Orlent H, Van Vlierberghe H, de Galocsy C, Peeters M, Padalko E, Van Gucht S, Vanwolleghem T. [Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.](#) J Viral Hepat. 2025 Feb;32(2):1-15. doi: 10.1111/jvh.14060. PMID: 39846497; PMCID: PMC11756033.

---

Liang X, Chen Q, Tang H, Guan Y, Liang M, Hu P, Xie W, Rao H, Niu J, Chen L, Yan L, Chen X, Li X, Zhao Y, Lenz O, Biermer M, Hou J. [Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus Infection.](#) J Clin Transl Hepatol. 2025 Apr 28;13(4):278-283. doi: 10.14218/JCTH.2024.00313. Epub 2025 Feb 24. PMID: 40206273; PMCID: PMC11976442.

---

Sandmann L, Windzio L, Bremer B, Falak S, Beheim-Schwarzbach J, Kummrow A, Cornberg M, Wedemeyer H, Maasoumy B, Valiente E. [Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits.](#) J Viral Hepat. 2025 Jun;32(6):e70036. doi: 10.1111/jvh.70036. PMID: 40372088; PMCID: PMC12080313.

---

Caviglia GP, Dileo E, Olivero A, Mengozzi G, Ciancio A, Loglio A, Viganò M, Fagiuoli S, Colombatto P, Coco B, Brunetto MR, Angrisani D, Galeota Lanza A, Magni C, Rizzardini G, Messina V, Milella M, Saracino A, Marinaro L, Cariti G, Cossiga V, Morisco F, Cretella S, Verucchi G, Biliotti E, D'Offizi G, Feasi M, Pontali E, Coppola C, Rapetti R, Pirisi M, Izzi A, Santantonio T, Di Marco V, Marrone A, Coppola N, Rizzi M, Cattelan AM, Niro GA, Toniutto P, Ponziani FR, Belli LS, Federico A, Bertino G, Barone M, Puoti M, Civolani A, Distefano M, Surace LA, Cozzolongo R, Cella EM, Teti E, Lampertico P, Stroffolini T, Rizzetto M; [HDV Describe Study Group. The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm.](#) Liver Int. 2025 Sep;45(9):e70242. doi: 10.1111/liv.70242. PMID: 40729522; PMCID: PMC12306849.

---

Aleman S, Wedemeyer H, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Chee G, Manuilov D, Li M, Lau A, Osinusi A, Tseng S, Zur Wiesch JS, Cornberg M, Zeuzem S, Lampertico P. [P-2191. Efficacy and safety of bulevirtide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study](#). Open Forum Infect Dis. 2025 Jan 29;12(Suppl 1):ofae631.2345. doi: 10.1093/ofid/ofae631.2345. PMID: PMC11778896.

---

Nguyen T, Vo VH, Le L, Luong AB, Nguyen CD, Quach PT, Trinh TT, Phan ST, Cao TN, Mai TBC, Hoang VA, Bui HH, Maldarelli F. [Unexpectedly low prevalence of hepatitis delta virus infection in Southern Viet Nam](#). Sci Rep. 2025 Dec 31;16(1):3307. doi: 10.1038/s41598-025-33268-0. PMID: 41476105; PMID: PMC12835169.

---

Rinaldi L, Viganò M, Ciancio A, Caturano A, Messina V, Niro GA, Capoluongo N, Loglio A, Marinaro L, Marrone A, Claar E, Russello M, Ciraci E, Gentilucci UV, Pace Palitti V, Acierno C, Cosentino C, Mormone A, Cotugno R, Terracciani F, Gallo P, Cannavò MR, Rosato V, Sasso FC, Petrucciello C, Petronio Petronio G, Villone G, Benanti F, Cariti G, Falbo E, Distefano M, Sacco R, Perrella A, Izzi A. [Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study](#). Viruses. 2025 Feb 12;17(2):251. doi: 10.3390/v17020251. PMID: 40007006; PMID: PMC11860205.

---

Furquim d'Almeida A, Ho E, Govaerts L, Michielsen P, Sersté T, Bourgeois S, Delwaide J, Moreno C, Orlent H, Van Vlierberghe H, de Galocsy C, Peeters M, Padalko E, Van Gucht S, Vanwolleghem T. [Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study](#). J Viral Hepat. 2025 Feb;32(2):1-15. doi: 10.1111/jvh.14060. PMID: 39846497; PMID: PMC11756033.

---

## 2024

Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P. [Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial](#). J Hepatol. 2024 Oct;81(4):621-629. doi: 10.1016/j.jhep.2024.05.001. Epub 2024 May 9. PMID: 38734383.

---

Anolli MP, Uceda Renteria S, Degasperis E, Facchetti F, Sambarino D, Borghi M, Perbellini R, Soffredini R, Monico S, Callegaro A, Lampertico P. [Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV](#). JHEP Rep. 2024 Dec 11;7(3):101299. doi: 10.1016/j.jhepr.2024.101299. PMID: 40051411; PMID: PMC11883403.

---



Anolli MP, Renteria SU, Degasperi E, Borghi M, Facchetti F, Sambarino D, Perbellini R, Monico S, Ceriotti F, Lampertico P. [Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods](#). Liver Int. 2024 Mar;44(3):831-837. doi: 10.1111/liv.15795. Epub 2024 Jan 22. PMID: 38247385.

---

Asselah T, Chulanov V, Lampertico P, et al. [Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D](#). The New England Journal of Medicine. 2024 Jul;391(2):133-143. DOI: 10.1056/nejmoa2314134. PMID: 38842520.

---

Illescas-López M, Chaves-Blanco L, de Salazar A, Hernández-Febles M, Carracedo R, Lagarejos E, Fuentes A, Pereira S, Cea M, De La Iglesia A, Freyre C, Iborra A, Odero V, García-Barrionuevo A, Aguilera A, Pena MJ, García F. [Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring](#). Front Cell Infect Microbiol. 2024 Jun 26;14:1422299. doi: 10.3389/fcimb.2024.1422299. PMID: 38988808; PMCID: PMC11233439.

---

Greco LI, Pavel-Tanasa M, Matei L, Sultana C, Ruta SM, Greco RI, Ursu RG, Cianga P, Iancu LS. [Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania](#). Pathogens. 2024 Sep 13;13(9):793. doi: 10.3390/pathogens13090793. PMID: 39338984; PMCID: PMC11435033.

---

Sapuk A, Steinhoff L, Huenninghaus K, Willuweit K, Rashidi Alavijeh J, Hild B, Asar L, Schmidt HH, Schramm C. [Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease](#). Can J Gastroenterol Hepatol. 2024 Jul 23;2024:2364031. doi: 10.1155/2024/2364031. PMID: 39081834; PMCID: PMC11288691.

---

Weichselbaum L, Njimi H, van den Wijngaert S, Dahma H, Nkuize M, Van Gossum M, Eisendrath P, Mulkey JP, Sersté T. [A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development](#). United European Gastroenterol J. 2024 May;12(4):516-525. doi: 10.1002/ueg2.12564. Epub 2024 Mar 22. PMID: 38520063; PMCID: PMC11091775.

---

## 2023

Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, Lütgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P; HDV RNA Assays Writing Group at the HBV Forum. [HDV RNA Assays: Performance characteristics, clinical utility and challenges](#). Hepatology. 2023 Aug 28. doi: 10.1097/HEP.0000000000000584. Epub ahead of print. PMID: 37640384.

---

Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. [A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D](#). N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. PMID: 37345876.

---

Lampertico P, Degasperis E, Sandmann L, Wedemeyer H; Delta Cure 2022 Working Group. [Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022](#). JHEP Rep. 2023 Jun 28;5(9):100818. doi: 10.1016/j.jhepr.2023.100818. PMID: 37593170; PMCID: PMC10428117.

---

Fasano M, Milella M, Carbonara S, Tundo P, Minniti S, Buccoliero G, Maci AM, Lo Caputo S, Santantonio TA. [Apulian infectious diseases network: survey on the prevalence of delta infection among chronic HBV carriers in Apulia](#). Front Public Health. 2023 Sep 26;11:1247454. doi: 10.3389/fpubh.2023.1247454. PMID: 37822539; PMCID: PMC10562714.

---

Deterding K, Xu C, Port K, Dietz-Fricke C, Xun J, Maasoumy B, Cornberg M, Wedemeyer H. [Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA](#). J Viral Hepat. 2023 Jul;30(7):597-606. doi: 10.1111/jvh.13831. Epub 2023 Mar 28. PMID: 36924318.

---

Mangia A, Squillante MM, Fraticelli F, Cavorsi MC, Paroni G, Zaffarano L, Piazzolla AV. [HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy](#). Cells. 2023; 12(10):1413. <https://doi.org/10.3390/cells12101413>.

---

Anolli MP, Degasperis E, Allweiss L, et al. [A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics](#). Journal of Hepatology. 2023 Jan;S0168-8278(22)03475-4. DOI: 10.1016/j.jhep.2022.12.023. PMID: 36931396.

---

Zi J, Li YH, Wang XM, Xu HQ, Liu WH, Cui JY, Niu JQ, Chi XM. [Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age](#). World J Gastroenterol. 2023 Oct 14;29(38):5395-5405. doi: 10.3748/wjg.v29.i38.5395. PMID: 37900584; PMCID: PMC10600800.

---

Etzion O, Hamid S, Lurie Y, Gane EJ, Yardeni D, Duehren S, Bader N, Nevo-Shor A, Channa SM, Cotler SJ, Mawani M, Parkash O, Dahari H, Choong I, Glenn JS. [Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LMT-1 clinical trial](#). Hepatology. 2023 Jun 1;77(6):2093-2103. doi: 10.1097/HEP.0000000000000309. Epub 2023 Feb 20. PMID: 36800850; PMCID: PMC10187621.

---



Jachs M, Panzer M, Hartl L, Schwarz M, Balcar L, Camp JV, Munda P, Mandorfer M, Trauner M, Aberle SW, Zoller H, Reiberger T, Ferenci P. [Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression](#). JHEP Rep. 2023 Apr 7;5(8):100751. doi: 10.1016/j.jhepr.2023.100751. PMID: 37360907; PMCID: PMC10285645.

---

Shekhtman L, Cotler SJ, Degaspero E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Facchetti F, Ceriotti F, Lampertico P, Dahari H. [Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations](#). JHEP Rep. 2023 Nov 15;6(2):100966. doi: 10.1016/j.jhepr.2023.100966. PMID: 38274491; PMCID: PMC10808955.

---

## 2022

Degaspero E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. [Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension](#). J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13. PMID: 35973578.

---

Olivero A, Rosso C, Ciancio A, Abate ML, Nicolosi A, Troshina G, Armandi A, Ribaldone DG, Saracco GM, Bugianesi E, Rizzetto M, Caviglia GP. [Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification](#). Biomedicines. 2022 Mar 29;10(4):792. doi: 10.3390/biomedicines10040792. PMID: 35453541; PMCID: PMC9029565.

---

Jachs M, Schwarz C, Panzer M, Binter T, Aberle SW, Hartl L, Dax K, Aigner E, Stättermayer AF, Munda P, Graziadei I, Holzmann H, Trauner M, Zoller H, Gschwantler M, Mandorfer M, Reiberger T, Ferenci P. [Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study](#). Aliment Pharmacol Ther. 2022 Jul;56(1):144-154. doi: 10.1111/apt.16945. Epub 2022 May 5. PMID: 35514008; PMCID: PMC9321570.

---

Yurdaydin C, Keskin O, Yurdcu E, Çalışkan A, Önem S, Karakaya F, Kalkan Ç, Karataylı E, Karataylı S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS. [A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis](#). Hepatology. 2022 Jun;75(6):1551-1565. doi: 10.1002/hep.32259. Epub 2021 Dec 23. PMID: 34860418.

---

## 2021

Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M, Olivero A, Miklau FN, **Nickel A, Reinhardt A, Dietzsch M**, Kessler HH. [Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study](#). J Clin Virol. 2021 Sep;142:104932. doi: 10.1016/j.jcv.2021.104932. Epub 2021 Jul 24. PMID: 34333392.

---

Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. [Poor clinical and virological outcome of nucleos\(t\)ide analogue monotherapy in HBV/HDV co-infected patients](#). Medicine (Baltimore). 2021 Jul 16;100(28):e26571. doi: 10.1097/MD.00000000000026571. PMID: 34260535; PMCID: PMC8284709.

---

Pflüger LS, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann JH, Pfefferle S, Dandri M, Schulze Zur Wiesch J, Lütgehetmann M. [Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system](#). JHEP Rep. 2021 Aug 28;3(6):100356. doi: 10.1016/j.jhepr.2021.100356. PMID: 34712932; PMCID: PMC8531665.

---

Urban S, Neumann-Haefelin C, Lampertico P. [Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease](#). Gut. 2021 Sep;70(9):1782-1794. doi: 10.1136/gutjnl-2020-323888. Epub 2021 Jun 8. PMID: 34103404; PMCID: PMC8355886.

---

Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. [Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study](#). Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. PMID: 33217778.

---

Jachs M, Binter T, Schmidbauer C, Hartl L, Strasser M, Laferl H, Hametner-Schreil S, Lindorfer A, Dax K, Stauber RE, Kessler HH, Bernhofer S, Maieron A, Loacker L, Bota S, Santonja I, Munda P, Mandorfer M, Peck-Radosavljevic M, Holzmann H, Gschwantler M, Zoller H, Ferenci P, Reiberger T. [Hepatitis D virus \(HDV\) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis](#). United European Gastroenterol J. 2021 Dec;9(10):1119-1127. doi: 10.1002/ueg2.12163. Epub 2021 Dec 7. PMID: 34873866; PMCID: PMC8672089.

---

Roggenbach I, Chi X, Lempp FA, Qu B, Walter L, Wu R, Gao X, Schnitzler P, Ding Y, Urban S, Niu J. [HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection](#). Viruses. 2021 Sep 10;13(9):1799. doi: 10.3390/v13091799. PMID: 34578380; PMCID: PMC8473203.

---



## 2020

Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. [Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study](#). Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. PMID: 33217778.

---

Kamal, H.; Westman, G.; Falconer, K.; Duberg, A.-S. [Long-term study of hepatitis delta virus infection at secondary care centers: The impact of viremia on liver-related outcomes](#). Hepatology 2020, 72, 1177–1190.

---

Abbas Z, Saad M, Asim M, Abbas M, Samejo SA. [The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D](#). Turk J Gastroenterol. 2020 Feb;31(2):136-141. doi: 10.5152/tjg.2020.18846. PMID: 32141822; PMCID: PMC7062136.

---

Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. [Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg](#). Sci Rep. 2020 May 12;10(1):7837. doi: 10.1038/s41598-020-64122-0. PMID: 32398799; PMCID: PMC7217939.

---

## 2019

Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. [Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation](#). Antivir Ther. 2019;24(2):117-123. doi: 10.3851/IMP3281. PMID: 30516520.

---

Loglio A. [Comparison of three HDV-RNA quantitative commercially available tests in untreated and in myrcludex-B treated patients with hdv related chronic hepatitis in a real-life setting](#). APASL Single Topic Conference Delta Hepatitis June 27-28, 2019 Baku, Azerbaijan. EURASIAN JOURNAL OF CLINICAL SCIENCES. DOI:10.28942/EJCS.V2I2.66

---

Rizzetto M, Smedile A. [Hepatitis D: Virology, management and methodology](#). Il Pensiero Scientifico Editore, 2019, Italy. ISBN: 978-88-490-0646-9

---

Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertoletti A, Lampertico P. [Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients](#). J Hepatol. 2019 Oct;71(4):834-839. doi: 10.1016/j.jhep.2019.07.003. Epub 2019 Jul 11. PMID: 31302176.

---

Wedemeyer, H.; Schoneweis, K.; Bogomolov, P.; Voronkova, N.; Chulanov, V.; Stepanova, T.; Allweiss, L.; Dandri, M.; Ciesek, S.; Haefeli, W.E.; et al. [Safety and efficacy of 10 mg \(High dose\) bulevirtide \(myrcludex B\) in combination with peg-interferon alpha 2a or tenofovir in patients with chronic HBV: HDV co-infection: Week 24 interim results of the MYR203 extension study](#). Hepatology 2019, 70 (Suppl. 1), 58A–59A. DOI: 10.1055/s-0039-3402105

---

## 2017

Wedemeyer, H.; Port, K.; Deterding, K.; Wranke, A.; Kirschner, J.; Bruno, B.; Martins, B.; Glenn, J.S.; Kornberg, M.; Manns, M.P. [A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis](#). J. Hepatol. 2017, 66, 524. DOI: 10.1016/S0168-8278(17)30310-0

---

## 2013

Brichler S, Le Gal F, Butt A, Chevret S, Gordien E. [Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia](#). Clin Gastroenterol Hepatol. 2013 Jun;11(6):734–40. doi: 10.1016/j.cgh.2013.01.025. Epub 2013 Feb 1. PMID: 23376798.

---

Chudy, Michael, Hanschmann, Kay-Martin, Bozdayi, Mithat, Kreß, Julia, C., Nübling, Micha. et al. (2013). [Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique \(NAT\)-based assays](#). World Health Organization.

---

## Contact

Roboscreen GmbH  
Hohmannstrasse 7  
04129 Leipzig  
GERMANY

Phone +49 341 989 734 0  
FAX +49 341 989 734 199  
info@roboscreen.com  
www.roboscreen.com

